CAC
PTGX icon

Cowen and Company’s Protagonist Therapeutics PTGX Stock Holding History

Cowen and Company’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-340,974
Closed -$15.3M – 233
2024
Q3 		$15.3M Sell
340,974
-841,294
-71% -$34M 0.52% 29
2024
Q2 		$41M Sell
1,182,268
-375,368
-24% -$11M 1.13% 15
2024
Q1 		$45.1M Buy
+1,557,636
New +$42.4M 1.75% 9
2023
Q4 		– Sell
-1,657,551
Closed -$27.6M – 652
2023
Q3 		$27.6M Hold
1,657,551
– – 1.93% 11
2023
Q2 		$45.8M Buy
+1,657,551
New +$41.5M 3.79% 4
2022
Q3 		– Sell
-1,065,724
Closed -$8.43M – 750
2022
Q2 		$8.43M Buy
1,065,724
+343,149
+47% +$4.15M 0.81% 30
2022
Q1 		$17.1M Buy
722,575
+719,397
+22,637% +$20.3M 1.65% 14
2021
Q4 		$109K Buy
+3,178
New +$100K 0.01% 361

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cowen and Company's PTGX Position: Q4 2024 in Review

Cowen and Company sold out of Protagonist Therapeutics (PTGX) in Q4 2024, closing a stake of 340,974 shares — an estimated $15.3M sold.

Cowen and Company first reported a position in PTGX in Q4 2021 and held it in 8 quarters. The position peaked at $45.8M in Q2 2023. 241 funds tracked by Wall St. Rank hold PTGX as of Q4 2024.

  • Cowen and Company reported no remaining Protagonist Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cowen and Company sold 340,974 Protagonist Therapeutics shares in Q4 2024, an estimated $15.3M.
  • Cowen and Company first reported a position in Protagonist Therapeutics in Q4 2021 and held it in 8 quarters.
  • Cowen and Company's Protagonist Therapeutics position peaked at $45.8M in Q2 2023.
  • 241 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.